Cumberland Pharmaceuticals Inc. (CPIX) is a Healthcare stock trading at $7.62 (as of 2026-08-21), with a market capitalization of $114.10M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Cumberland Pharmaceuticals Inc. develops and commercializes prescription specialty drugs for hospital acute care, gastroenterology, rheumatology, and oncology, including products such as Acetadote, Caldolor, and Kristalose, and it earns money primarily from sales of its FDA-approved brands.
With specialty drugs, the profit model is driven by commercialization revenue from FDA-approved brands, and when that revenue base is small, high gross margin can still translate into a sizable operating loss.
| FDA Brands | $0.0B |
| Discontinued | $0.0B |
Business quality (Weak): High gross margin exists alongside a negative operating margin, which suggests profitability depends heavily on scaling revenue from its FDA-approved branded products.
| Price | $7.62 |
| Market Cap | $114.10M |
| Price / Book | 6.67 |
| Price / Sales | 4.01 |
| FCF Yield | 9.1% |
| DCF Value (model) | $6.88 |
| DCF Upside vs Price | -9.7% |
| Revenue (TTM) | $44.52M |
| Net Margin | -6.4% |
| Revenue Growth (YoY) | -22.0% |
| EPS Growth (YoY) | -375.0% |
| FCF Growth (YoY) | -89.9% |
| Altman Z-Score | 1.28 (distress) |
| Piotroski F-Score | 6/9 (moderate) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| Top Institutional Holder | Ikarian Capital, LLC ($1.80M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | A. J. Kazimi |
| Employees | 91 |
| Country | US |
| IPO Date | 2009-08-11 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.